Lv31
212 积分 2024-09-23 加入
Bispecific antibodies for cancer therapy: evolution of structural formats and co-targeting strategies from wet-lab to AI-driven in silico modeling
2小时前
待确认
Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation
3天前
已完结
Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies
15天前
已完结
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
16天前
已完结
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
30天前
已完结
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Designed for Optimal CD137 Engagement Resulting in Potent Conditional T-Cell Activity
1个月前
已关闭
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
1个月前
已完结
Stepping forward in antibody-drug conjugate development
1个月前
已完结
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity
1个月前
已完结
Multi-specific antibody drug conjugate: The next frontier for solid tumors
1个月前
已完结
皖公网安备34019202002308
